---
layout: phenotype
title: Methicillin-resistant Staphylococcus Aureus (Mrsa)
phenotype_id: GYRFUq2n8xWsxadvasad6d
name: Methicillin-resistant Staphylococcus Aureus (Mrsa)
type: Disease or Syndrome
group: 
sources: 
    - clinicalcodes
data_sources:
    - Clinical Practice Research Datalink GOLD
clinical_terminologies:
    - Read Version 2
    - OXMIS
validation:
codelists: SchneiderLindner_Mrsa_GYRFUq2n8xWsxadvasad6d_OXMISRead.csv
valid_event_data_range: 01/01/1993 - 31/12/2007
sex:
    - Female
    - Male
author:
    - Verena Schneider-Lindner
    - Caroline Quach
    - James A Hanley
    - Samy Suissa       
publications:
    - Verena Schneider-Lindner, Caroline Quach, James A Hanley, Samy Suissa, Antibacterial Drugs and the Risk of Community-Associated Methicillin-Resistant Staphylococcus aureus in Children. Arch Pediatr Adolesc Med, 165(12), 2011.
status: FINAL
date: 2011-08-01
modified_date: 2011-08-01
version: Revision 1
---

### Primary Care

{% include csv.html csvdata=site.data.codelists.SchneiderLindner_Mrsa_GYRFUq2n8xWsxadvasad6d_OXMISRead %}

### Implementation

Design: 
Population-based case-control study in children 1 to 19 years of age.

Setting: 
Primary care, General Practice Research Database, United Kingdom, 1994-2007.

Participants: 
Cases were children who had MRSA diagnosed as outpatients, and controls were individually matched on age and practice, with the matched caseâ€™s diagnosis date as the index date for both.

Main Exposures: 
Antibacterial agents prescribed 180 to 30 days prior to the index date, excluding prescriptions 30 days before the index date to prevent protopathic bias.

Outcome Measures: 
Rate ratios (RRs) estimated from the odds ratios of exposure in cases compared with controls using conditional logistic regression, adjusted for comorbid conditions, other prescription drug use, and hospitalization.

Results: 
The rate of MRSA was 4.5 per 100 000 per year. Of 297 cases and 9357 controls, 52.5% and 13.6%, respectively, received antibacterial drug prescriptions during the 150-day exposure window. The adjusted RR with any antibacterial drug was 3.5 (95% confidence interval [CI], 2.6-4.8). The RRs increased with the number of prescriptions (2.2 [95% CI, 1.5-3.2], 3.3 [95% CI, 1.9-5.6], 11.0 [95% CI, 5.6-21.6], and 18.2 [95% CI, 9.4-35.4] for 1, 2, 3, and >=4 prescriptions, respectively). The RR was particularly elevated for quinolones at 14.8 (95% CI, 3.9- 55.8), with wide variation among antibacterial classes.

### Publications

<pre>
Verena Schneider-Lindner, Caroline Quach, James A Hanley, Samy Suissa, Antibacterial Drugs and the Risk of Community-Associated Methicillin-Resistant Staphylococcus aureus in Children. Arch Pediatr Adolesc Med, 165(12), 2011.
</pre>
